cagrilintide

Cagrilintide Research Peptide: Comprehensive Amylin-Receptor Guide

Cagrilintide research peptide, also known by the development codes AM833 and NN0174-0833, is a lipidated, long-acting analogue of the pancreatic hormone amylin. Investigators use the molecule to study calcitonin-family receptor pharmacology, cyclic-AMP signaling, receptor selectivity, peptide lipidation, albumin interaction, aggregation resistance, and analytical method performance. Unlike a single-molecule GLP-1 receptor agonist, cagrilintide primarily activates amylin receptors (AMYRs) and the calcitonin receptor (CTR). Its combination with a separate GLP-1 analogue is a distinct experimental strategy rather than evidence that cagrilintide itself directly targets GLP-1R.

This listing supplies material exclusively for qualified laboratory research. The available vial configurations are catalog pack sizes, not experimental or clinical doses. The material is not a medicine, compounded preparation, dietary supplement, diagnostic product, or material for human or animal administration. Accordingly, this page provides no injection, self-experimentation, weight-management, treatment, or clinical dosing instructions.

Molecular and Product Overview

Product name	Cagrilintide research peptide
Development identifiers	AM833; NN0174-0833
CAS Registry Number	1415456-99-3
Molecule class	Lipidated, long-acting amylin analogue and nonselective calcitonin-family receptor agonist
Sequence length	38 residues in the standardized PubChem record, including a noncanonical residue designation
Molecular formula	C194H312N54O59S2
Approximate molecular mass	4409 g/mol; confirm the exact lot form, counterion, and hydration state by certificate and mass analysis
Primary research targets	Amylin receptors (CTR/RAMP complexes) and calcitonin receptor
Common in-vitro readouts	cAMP accumulation, Gs signaling, receptor occupancy, recruitment and trafficking assays, kinetic responses, and cell-based reporter activity
Listing configurations	5 mg × 10 vials or 10 mg × 10 vials
Use restriction	Laboratory research only; not for diagnosis, consumption, compounding, or human or animal use

Catalog mass does not by itself establish identity, purity, potency, sterility, endotoxin status, or suitability for a particular model. Researchers should review the certificate for the exact lot received and independently qualify the material for the intended method. In addition, they should distinguish the neutral molecular formula from salts, counterions, water, residual solvents, and formulation components when reconciling gravimetric and mass-spectrometric data.

Structural Design and Physicochemical Features

Native human amylin is a 37-residue peptide with a disulfide-constrained N-terminal region and a strong tendency to form amyloid fibrils. Those properties complicate formulation, handling, and long-duration experiments. Cagrilintide emerged from structure-activity work designed to preserve useful receptor pharmacology while reducing fibrillation and extending molecular exposure. Its engineered sequence, disulfide topology, and lipid conjugation make it a useful tool for comparing native amylin, shorter-acting analogues, and long-acting amylinomimetic designs.

PubChem lists cagrilintide under CID 171397054 with molecular formula C194H312N54O59S2 and a computed molecular weight near 4409 g/mol. The standardized record encodes 38 residues, including a noncanonical residue represented by “X.” Researchers should consult an authoritative structural record and the lot certificate before using a sequence in peptide mapping, theoretical mass calculations, or impurity assignments. A simplified one-letter string alone may omit information about lipid attachment, residue configuration, disulfide connectivity, terminal chemistry, or counterions.

Lipidation can increase reversible association with albumin and alter apparent exposure. In vitro, it can also change adsorption to plastic, chromatographic retention, free ligand concentration, recovery, and matrix effects. Therefore, nominal concentration should not automatically be treated as receptor-accessible concentration. Protein content, surface material, detergent choice, mixing, incubation time, and sample history should be controlled and reported.

Mechanisms Relevant to Laboratory Research

1. Amylin-Receptor Complex Activation

Amylin receptors are heteromeric complexes formed when the calcitonin receptor associates with receptor activity-modifying proteins, commonly RAMP1, RAMP2, or RAMP3. These combinations generate AMY1, AMY2, and AMY3 receptor phenotypes with different ligand preferences and cellular behavior. Cagrilintide research can therefore compare matched CTR-only and CTR/RAMP systems rather than treating “the amylin receptor” as a single uniform target.

2. Calcitonin-Receptor Agonism

Pharmacological profiling has described AM833 as a nonselective agonist across amylin-receptor and calcitonin-receptor systems. This property distinguishes it from receptor-selective probes. Appropriate experiments should include receptor-null cells, CTR-only cells, separate RAMP co-expression models, native amylin, calcitonin-family comparators, and a qualified reference material. Such a design helps separate target-dependent signaling from reporter amplification or nonspecific cell responses.

3. Gs and cAMP Signaling

CTR and AMYR systems commonly couple to Gs, activate adenylate cyclase, and increase intracellular cAMP. Concentration-response experiments can estimate potency, maximal effect, slope, and relative activity across receptor configurations. However, receptor density, RAMP expression, assay time, phosphodiesterase activity, amplification, and cell background can change the apparent values. Results are most interpretable when all ligands use the same plate design, incubation window, normalization rules, and curve-fitting model.

4. Receptor Binding Geometry

Structural work has examined how cagrilintide engages AMY1R and CTR and how features of the peptide support receptor activation. Cryo-electron microscopy and functional analysis reported related binding modes at both receptors, providing hypotheses for nonselective activity. These models can guide mutagenesis, competition, and structure-function experiments, but a structure represents a defined experimental state. Researchers should not assume that one static complex captures every kinetic or conformational state in living cells.

5. Lipidation and Albumin Interaction

The lipid moiety supports long-acting behavior through reversible protein association and altered clearance in clinical research. In a laboratory assay, the same chemistry can affect solubility, adsorption, nonspecific binding, and recovery. Matched experiments with defined albumin concentrations can help quantify matrix dependence. Total measured analyte, unbound analyte, and receptor-active material should be distinguished whenever the study question requires that resolution.

6. Fibrillation and Aggregation Resistance

Amylin-based peptides require special attention to self-association. The medicinal-chemistry program that produced cagrilintide sought improved physical stability relative to native amylin, yet no peptide material should be assumed aggregate-free under every condition. Researchers can evaluate time-, temperature-, concentration-, and surface-dependent behavior using size-exclusion chromatography, light scattering, microscopy, sedimentation, or other qualified orthogonal methods.

7. Receptor Trafficking and Desensitization

Extended ligand exposure can change receptor internalization, recycling, desensitization, and downstream response duration. Imaging, surface-labeling, complementation, and kinetic biosensor assays can examine these processes. Because RAMP identity can influence receptor localization and trafficking, experiments should document the exact receptor construct, expression ratio, cell background, and exposure time.

8. Complementary Combination Research

Cagrilintide has been studied alongside semaglutide because amylin-family and GLP-1 pathways are mechanistically distinct yet potentially complementary. A combination study should include each single agent, the combination, vehicle, and receptor-specific controls. Apparent additivity or synergy should be tested with a predefined quantitative model rather than inferred from a larger raw response. Importantly, clinical trial combinations do not establish a safe protocol for research products, self-use, or unapproved compounding.

Appropriate Research Applications

Receptor Pharmacology Panels

Engineered cells expressing CTR alone or CTR with individual RAMPs can map potency and efficacy across calcitonin-family receptors. cAMP, label-free impedance, dynamic mass redistribution, or transcriptional reporters provide complementary endpoints. Parental cells and viability measurements help identify nonspecific signal changes, while native amylin, calcitonin, and a selective comparator anchor the response window.

Structure–Activity Relationship Studies

Researchers can compare cagrilintide with native amylin, pramlintide, and experimental analogues to examine how residue substitutions, lipidation, terminal chemistry, and disulfide topology influence activity and physical stability. A well-controlled panel uses verified identity, normalized active content, matched matrices, and the same receptor system. Computational predictions are most useful when tested against binding, functional, and analytical measurements.

Albumin and Matrix-Effect Studies

Equilibrium methods, surface-based assays, ultrafiltration, size-exclusion approaches, or validated bioanalytical formats can investigate albumin association and apparent free fraction. Researchers should compare protein-free and protein-containing matrices, document albumin source and fatty-acid status, and test recovery from the actual labware. These controls are especially important when two analogues carry different lipid moieties.

Aggregation and Stability Method Development

Cagrilintide is suitable for developing stability-indicating assays that distinguish intact peptide from oxidation, deamidation, truncation, conjugation changes, adsorption loss, particulates, and high-molecular-weight species. Stress conditions should be scientifically justified and separated from routine storage. An apparent loss in chromatographic peak area may reflect degradation, aggregation, precipitation, adsorption, or sample-preparation bias, so orthogonal investigation is necessary.

Comparative Incretin and Metabolic-Signaling Research

Although cagrilintide is not itself a GLP-1R agonist, it can be included in a comparative panel with GLP-1, GIP, glucagon, and amylin-pathway research tools. Such studies can map receptor-specific signaling, transcriptional responses, cellular energetics, or pathway interactions. Mechanistic comparisons require receptor-selective controls and do not justify extrapolating a research-reagent result to clinical efficacy.

Clinical-Literature Translation

Published trials provide hypotheses about pharmacokinetics, tolerability, and complementary pathway biology. For example, early clinical research reported a long elimination half-life and later phase 2 and phase 3 programs evaluated cagrilintide alone or with semaglutide. Those observations belong to regulated investigational products under controlled protocols. A catalog research material is not interchangeable with the studied formulation and should not be represented as an approved drug.

Analytical and Quality-Control Framework

1. Confirm provenance. Record supplier, lot, stated form, manufacturing date, storage history, vial condition, and all available documentation.
2. Verify identity. Combine intact-mass analysis with peptide mapping, chromatographic comparison, disulfide assessment, or another orthogonal identity method.
3. Assess related substances. Use a qualified chromatographic method to examine oxidation, deamidation, truncation, lipid-linker variants, and other process- or storage-related impurities.
4. Evaluate aggregation. Apply size-exclusion or another suitable technique and distinguish soluble aggregates, particulates, precipitation, and adsorption loss.
5. Confirm functional activity. Generate full concentration-response curves in defined AMYR and CTR systems with qualified controls and prespecified acceptance criteria.
6. Check mass balance. Consider counterions, water, residual solvents, buffer components, and non-peptide material when interpreting weighed mass.
7. Qualify model-relevant impurities. Evaluate endotoxin, bioburden, particulates, or synthesis residuals when the experimental system requires those attributes.
8. Retain raw data. Preserve chromatograms, spectra, plate maps, images, integration settings, curve-fitting rules, and reserve samples.

A stated HPLC area percentage does not prove identity, potency, sterility, endotoxin status, or suitability for every model. Likewise, a matching intact mass cannot exclude positional isomers, low-level impurities, aggregation, or altered receptor activity. Fit-for-purpose qualification should combine chemical, physical, and functional evidence.

Experimental Design Controls

Good cagrilintide experiments resolve receptor composition. At minimum, teams should compare parental cells, CTR-only cells, and selected CTR/RAMP combinations. They should also include vehicle, a native ligand, and a qualified comparator. Receptor and RAMP expression should be quantified when possible because expression imbalance can create apparent selectivity that does not reflect intrinsic pharmacology.

For combination studies, each component and the combination should be tested at matched time points. Investigators should define whether they are evaluating additivity, potentiation, synergy, or pathway independence and select an appropriate analysis model before seeing the results. Cell health, assay ceiling effects, and signal amplification must be evaluated so a larger response is not mistaken for a true interaction.

Lot comparisons should use the same reference material and the same qualified method. System-suitability controls belong on every run, and relative potency estimates should include confidence intervals. A changed response can originate from the peptide, receptor expression, RAMP abundance, albumin content, cell health, plate performance, or data processing; therefore, independent evidence is essential.

Laboratory Handling and Stability

Qualified personnel should handle cagrilintide research material under a written institutional risk assessment. Use laboratory-appropriate personal protective equipment, avoid aerosol generation and accidental exposure, and segregate the material from food, medicines, clinical supplies, and personal-use devices. This page does not establish a hazard classification and does not replace lot-specific safety documentation.

Follow the lot label and certificate for storage. Peptide stability can depend on temperature, light, moisture, oxygen, container surface, concentration, formulation, and repeated temperature cycling. Laboratories should therefore validate stability in the actual matrix and container used by their method, minimize avoidable handling cycles, and record preparation time, storage history, and freeze–thaw events.

If analytical solutions are required, researchers should use an institutionally approved, method-specific protocol based on solubility and stability testing. This product page intentionally provides no reconstitution volume, injection concentration, clinical dose, route, or administration procedure. Never administer this research material to a person or animal, and never substitute it for a regulated investigational or pharmacy-dispensed product.

Frequently Asked Questions

1. What is cagrilintide?

Cagrilintide is an engineered, lipidated, long-acting analogue of amylin. It is also known as AM833 or NN0174-0833. Researchers use it to study amylin and calcitonin receptors, Gs/cAMP signaling, receptor-complex selectivity, lipidation, albumin interaction, aggregation behavior, and analytical methods. This catalog material is a laboratory reagent, not a licensed medicine.

2. Is cagrilintide a GLP-1 receptor agonist?

No. Cagrilintide primarily acts at calcitonin-family receptor systems, including AMY receptors and CTR. It has been clinically studied with the separate GLP-1 analogue semaglutide, but that combination does not make cagrilintide a direct GLP-1R agonist. Researchers should include receptor-specific controls when comparing these pathways.

3. Which assays are useful for cagrilintide research?

Common approaches include cAMP accumulation, transcriptional reporters, binding or competition assays, kinetic biosensors, receptor internalization, surface-expression analysis, albumin-binding studies, LC-MS, reversed-phase chromatography, and size-exclusion analysis. Ideally, functional studies use defined CTR and CTR/RAMP systems and are supported by orthogonal chemical characterization.

4. Does an HPLC purity value prove the material is suitable?

No. HPLC area percentage depends on the method and detector. It does not independently establish molecular identity, active content, receptor potency, sterility, endotoxin status, aggregation, or suitability for a particular model. Review the lot certificate, understand the method, and perform independent qualification that matches the experiment’s risks and acceptance criteria.

5. Are the 5 mg and 10 mg options recommended doses?

No. They are catalog fill-size labels supplied in ten-vial configurations. They are not clinical doses, animal-study doses, recommended assay concentrations, or administration instructions. Experimental concentrations must be justified by the investigator, receptor system, assay range, material qualification, institutional controls, and applicable regulations.

6. Can cagrilintide be combined with semaglutide or another peptide?

A laboratory may investigate combinations under an approved research protocol, using each single component, the combination, vehicle, receptor-specific controls, and a predefined interaction model. Published clinical combinations do not establish compatibility or safety for catalog reagents. This material must not be mixed for injection, personal use, compounding, or unapproved treatment.

7. Can this material be used for weight loss or diabetes treatment?

No. Hanpro supplies this cagrilintide material only for nonclinical laboratory research. It is not for injection, ingestion, diagnosis, treatment, compounding, or human or animal administration. Clinical questions require a licensed healthcare professional and appropriately approved products; research literature must not be converted into self-use instructions.

Related Research Materials

• Cagrilintide + Semaglutide — a predefined combination research material for controlled analytical comparisons.
• Semaglutide — a selective GLP-1R agonist analogue for receptor-pathway comparisons.
• Tirzepatide — a dual GIPR/GLP-1R research peptide with a different target profile.
• Retatrutide — a multi-receptor research peptide for GIPR, GLP-1R, and glucagon-receptor models.
• Mazdutide — a dual GLP-1R/glucagon-receptor research peptide.
• Survodutide — another GLP-1R/glucagon-receptor research agonist.
• AICAR — a small-molecule research material for AMPK and cellular-energy studies.
• NAD+ — a cofactor research material for redox and metabolic-assay development.
• MOTS-c — a mitochondrial-derived peptide for metabolic-stress signaling research.
• SS-31 — a mitochondria-targeted research peptide for cardiolipin and bioenergetic models.

Quality Documentation

Researchers should request the certificate that applies to the exact lot received. Useful documentation may include identity data, chromatographic purity, mass analysis, stated peptide form, water or counterion information, and other lot-specific tests. Methods and specifications can vary, so the receiving laboratory remains responsible for determining whether the evidence supports its intended use.

Do not infer sterile status, clinical grade, validated potency, endotoxin limits, or absence of a specific impurity unless lot documentation explicitly tests and supports that property. Retain receiving records, analytical raw data, and reserve material when traceability matters. Independent confirmation protects data integrity and downstream interpretation.

Selected Authoritative References

1. Lau DCW, et al. Once-weekly cagrilintide for weight management: a randomized phase 2 trial. View the PubMed record.
2. Fletcher MM, et al. AM833 pharmacology across calcitonin-family receptor systems. View the PubMed record.
3. Kruse T, et al. Development of cagrilintide, a long-acting amylin analogue. View the PubMed record.
4. Enebo LB, et al. Pharmacokinetics and pharmacodynamics of cagrilintide with semaglutide in a phase 1b trial. View the PubMed record.
5. Ma S, et al. Structural and mechanistic analysis of cagrilintide at amylin and calcitonin receptors. View the PubMed record.
6. PubChem. Cagrilintide, CID 171397054. View the compound record.

Research-use disclaimer: This cagrilintide material is supplied exclusively for nonclinical laboratory research by qualified professionals. It is not a medicine, compounded preparation, diagnostic device, food, dietary supplement, cosmetic, or veterinary product. It is not for injection, ingestion, weight management, diabetes treatment, diagnosis, patient use, or human or animal administration. Nothing on this page is medical advice. Investigators are responsible for biosafety assessment, legal and ethics review, method validation, safe disposal, and compliance with all applicable institutional and jurisdictional requirements.